Einträge von Halmos, Gabor auf dem Publikationsserver
 | Eine Stufe nach oben |
Anzahl der Einträge: 5.
2010
Hohla, Florian, Buchholz, Stefan, Schally, Andrew V. 
, Krishan, Awtar, Rick, Ferenc G. , Szalontay, Luca, Papadia, Andrea , Halmos, Gabor, Koster, Frank, Aigner, Elmar, Datz, Christian und Seitz, Stephan
(2010)
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer Letters 294 (1), S. 35-42.
Volltext nicht vorhanden.
, Krishan, Awtar, Rick, Ferenc G. , Szalontay, Luca, Papadia, Andrea , Halmos, Gabor, Koster, Frank, Aigner, Elmar, Datz, Christian und Seitz, Stephan
(2010)
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer Letters 294 (1), S. 35-42.
Volltext nicht vorhanden.
2009
Hohla, Florian, Buchholz, Stefan, Schally, Andrew V , Seitz, Stefan, Rick, Ferenc G. , Szalontay, Luca, Varga, Jozsef L., Zarandi, Marta, Halmos, Gabor, Vidaurre, Irving, Krishan, Awtar, Kurtoglu, Metin, Chandna, Sudhir , Aigner, Elmar und Datz, Christian
(2009)
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell Cycle 8 (19), S. 3149-3156.
Volltext nicht vorhanden.
, Seitz, Stefan, Rick, Ferenc G. , Szalontay, Luca, Varga, Jozsef L., Zarandi, Marta, Halmos, Gabor, Vidaurre, Irving, Krishan, Awtar, Kurtoglu, Metin, Chandna, Sudhir , Aigner, Elmar und Datz, Christian
(2009)
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell Cycle 8 (19), S. 3149-3156.
Volltext nicht vorhanden.
Seitz, Stephan, Schally, Andrew V. , Treszl, Andrea, Papadia, Andrea , Rick, Ferenc , Szalontay, Luca, Szepeshazi, Karoly, Ortmann, Olaf, Halmos, Gabor, Hohla, Florian und Buchholz, Stefan
(2009)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-Cancer Drugs 20 (7), S. 553-558.
Volltext nicht vorhanden.
, Treszl, Andrea, Papadia, Andrea , Rick, Ferenc , Szalontay, Luca, Szepeshazi, Karoly, Ortmann, Olaf, Halmos, Gabor, Hohla, Florian und Buchholz, Stefan
(2009)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-Cancer Drugs 20 (7), S. 553-558.
Volltext nicht vorhanden.
2007
Buchholz, Stefan, Schally, Andrew V. , Engel, Jörg B. , Hohla, Florian, Heinrich, Elmar, Koester, Frank, Varga, Jozsef L. und Halmos, Gabor
(2007)
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences 104 (6), S. 1943-1946.
Volltext nicht vorhanden.
, Engel, Jörg B. , Hohla, Florian, Heinrich, Elmar, Koester, Frank, Varga, Jozsef L. und Halmos, Gabor
(2007)
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences 104 (6), S. 1943-1946.
Volltext nicht vorhanden.
2006
Buchholz, Stefan, Keller, Gunhild, Schally, Andrew V. , Halmos, Gabor, Hohla, Florian, Heinrich, Elmar, Koester, Frank, Baker, Benjamin und Engel, Jörg B.
(2006)
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences 103 (27), S. 10403-10407.
Volltext nicht vorhanden.
, Halmos, Gabor, Hohla, Florian, Heinrich, Elmar, Koester, Frank, Baker, Benjamin und Engel, Jörg B.
(2006)
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences 103 (27), S. 10403-10407.
Volltext nicht vorhanden.